Amylyx Pharmaceuticals (AMLX) Inventory Average (2022 - 2023)
Amylyx Pharmaceuticals (AMLX) posted Inventory Average of $35.3 million for Q4 2023, up 23.53% on a QoQ basis from $28.6 million in Q3 2023, and up 584.25% year-over-year from $5.2 million in Q4 2022.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Inventory Average (2022 - 2023) Analysis & Trends
Amylyx Pharmaceuticals has reported Inventory Average for 2 years, with the latest figure at $35.3 million in Q4 2023.
- On a quarterly basis, Inventory Average rose 584.25% year-over-year to $35.3 million in Q4 2023; TTM through Dec 2023 was $35.3 million, a 584.25% increase from a year earlier, with the FY2023 full-year figure at $24.0 million, changed N/A from the prior year.
- Inventory Average was $35.3 million for Q4 2023 at Amylyx Pharmaceuticals, up from $28.6 million in the prior quarter.
- The five-year high for Inventory Average was $35.3 million in Q4 2023, with the low at $5.2 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 6.20 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 1.93 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 1.77 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 3.09 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | 213.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 90.57 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 2.17 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 35.35 Mn |
| Sep 30, 2023 | 28.62 Mn |
| Jun 30, 2023 | 18.97 Mn |
| Mar 31, 2023 | 11.42 Mn |
| Dec 31, 2022 | 5.17 Mn |